packageLifileucel

lifileucel

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Lifileucel, an autologous tumour-infiltrating lymphocyte cell therapy, is an antineoplastic treatment for melanoma. It is approved in the United States, but its marketing application in the European Union was withdrawn.

Unverified — written by glm-5.3-flash from general knowledge (no Wikidata entry found) and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:lifileucel
ATC codes:L01XL11
DrugBank:DB17107

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown